{"id":"NCT01536574","sponsor":"GlaxoSmithKline","briefTitle":"Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528","officialTitle":"An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09-02","primaryCompletion":"2012-03-01","completion":"2012-03-28","firstPosted":"2012-02-22","resultsPosted":"2012-12-13","lastUpdate":"2018-08-13"},"enrollment":295,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Requip PR","otherNames":[]}],"arms":[{"label":"Requip PR","type":"EXPERIMENTAL"}],"summary":"This open label extension study allows assessment of the long term safety profile of REQUIP PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.\n\nSubjects must not have a break in study medication between completing the feeder study and entering extension study, treatment must be continuous.\n\nSubjects will be dispensed down-titration medication at the study completion/early withdrawal visit and should be scheduled to return for a follow up visit 4 to 14 days after the last dose of study medication.","primaryOutcome":{"measure":"Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase)","timeFrame":"From the start of treatment (Baseline) up to Week 25","effectByArm":[{"arm":"Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study","deltaMin":58,"sd":null},{"arm":"Placebo in Parent DB Study, Ropinirole PR in OL Study","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["China"]},"refs":{"pmids":["25586298"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":162},"commonTop":["Dyskinesia","Dizziness","Nausea","Hallucination","Somnolence"]}}